NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 1027-1035

  Moon, Du G ^a,b   Lee, Sang E ^c   Oh, Mi M ^a,b   Lee, Sang C ^c   Jeong, Seong J ^c   Hong, Sung K ^c   Yoon, Cheol Y ^a,b   Byun, Seok S ^c   Park, Hong S ^a,b   Cheon, Jun ^d  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d College of Medicine   (South Korea)

Author keywords

Carcinoma; Cisplatin; NVP BEZ235; Resistance; Urinary bladder

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; DACTOLISIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL SURVIVAL; CONCENTRATION RESPONSE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; CELL CYCLE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84904397559     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2505     Document Type: Article

References (39)

1. Fossa SD, Aass N, Ous S, et al: Survival after curative treatment of muscle-invasive bladder cancer. Acta Oncol 35 (Suppl 8): 59-65, 1996.
2. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15: 2564-2569, 1997. (Pubitemid 27289886)
3. Hoda MA, Mohamed A, Ghanim B, et al: Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 6: 852-863, 2011.
4. O'Reilly T, McSheehy PM, Wartmann M, et al: Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22: 58-78, 2011.
5. Chen P, Wang L, Liu B, et al: EGFR-targeted therapies combined with chemotherapy for treating advanced non-smallcell lung cancer: a meta-analysis. Eur J Clin Pharmacol 67: 235-243, 2011.
6. Pinto-Leite R, Botelho P, Ribeiro E, et al: Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res 28: 3, 2009.
7. Wu X, Obata T, Khan Q, et al: The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93: 143-150, 2004. (Pubitemid 38112985)
8. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23: 675-680, 2009.
9. Garcia JA and Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354, 2008.
10. Thallinger C, Poeppl W, Pratscher B, et al: CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 79: 207-213, 2007. (Pubitemid 46848540)
11. Ma BB, Lui VW, Hui EP, et al: The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 28: 413-420, 2010.
12. Yardley DA: Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer 7: 7-22, 2013.
13. Chiong E, Lee IL, Dadbin A, et al: Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17: 2863-2873, 2011.
14. Fechner G, Classen K, Schmidt D, et al: Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 73: 665-669, 2009.
15. Wu C, Wangpaichitr M, Feun L, et al: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4: 25, 2005.
16. Manara MC, Nicoletti G, Zambelli D, et al: NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540, 2010.
17. Mukherjee B, Tomimatsu N, Amancherla K, et al: The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14: 34-43, 2012.
18. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
19. Buckwold VE, Wei J, Wenzel-Mathers M, et al: Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother 47: 2293-2298, 2003. (Pubitemid 36753585)
20. Tarbet EB, Maekawa M, Furuta Y, et al: Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res 94: 103-110, 2012.
21. Vilhelmova N, Jacquet R, Quideau S, et al: Three-dimensional analysis of combination effect of ellagitannins and acyclovir on herpes simplex virus types 1 and 2. Antiviral Res 89: 174-181, 2011.
22. Lee S, Choi EJ, Jin C, et al: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005. (Pubitemid 40403670)
23. Altomare DA, Wang HQ, Skele KL, et al: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004. (Pubitemid 39093031)
24. Fahy BN, Schlieman MG, Virudachalam S, et al: Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198: 591-599, 2004. (Pubitemid 38446534)
25. Zhang HY, Zhang PN and Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 146: 81-86, 2009.
26. Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063, 2011.
27. Rao YK, Wu AT, Geethangili M, et al: Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. Chem Res Toxicol 24: 238-245, 2011.
28. Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591: 124-127, 2008.
29. Mabuchi S, Kawase C, Altomare DA, et al: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15: 5404-5413, 2009.
30. Yasumizu Y, Miyajima A, Kosaka T, et al: Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol 191: 227-234, 2014.
31. Mansure JJ, Nassim R, Chevalier S, et al: Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 8: 2339-2347, 2009.
32. Yang F, Qian XJ, Qin W, et al: Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLoS One 8: e59879, 2013.
33. Schult C, Dahlhaus M, Glass A, et al: The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts antiproliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res 32: 463-474, 2012.
34. Bhatt AP, Bhende PM, Sin SH, et al: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463, 2010.
35. Roccaro AM, Sacco A, Husu EN, et al: Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115: 559-569, 2010.
36. Winter JN, Fox TE, Kester M, et al: Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol 299: C335-C344, 2010.
37. Zitzmann K, Ruden J, Brand S, et al: Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295: 100-109, 2010.
38. Aziz SA, Jilaveanu LB, Zito C, et al: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 16: 6029-6039, 2010.
39. Haagensen EJ, Kyle S, Beale GS, et al: The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106: 1386-1394, 2012.